N
BXRX

Nuveen’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Nuveen’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-31
Closed -$108K – 3406
2020
Q1 		$108K Sell
31
-48
-61% -$453K ﹤0.01% 3060
2019
Q4 		$769K Buy
+79
New +$674K ﹤0.01% 2782

Other funds holding BXRX

NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Nuveen's BXRX Position: Q2 2020 in Review

Nuveen sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q2 2020, closing a stake of 31 shares — an estimated $108K sold.

Nuveen first reported a position in BXRX in Q4 2019 and held it in 2 quarters. The position peaked at $769K in Q4 2019. 38 funds tracked by Wall St. Rank hold BXRX as of Q2 2020.

  • Nuveen reported no remaining Baudax Bio, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Nuveen sold 31 Baudax Bio, Inc. Common Stock shares in Q2 2020, an estimated $108K.
  • Nuveen first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Nuveen's Baudax Bio, Inc. Common Stock position peaked at $769K in Q4 2019.
  • 38 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2020.

Based on Nuveen's 13F filing for Q2 2020, filed 14 Aug 2020.